Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

To assess the efficacy of tocilizumab (TCZ) in giant cell arteritis (GCA) patients with refractory disease and/or with unacceptable side effects due to corticosteroids.A retrospective multicenter open-label study on 22 GCA patients treated with TCZ at standard dose of 8mg/kg/month. The main outcomes were achievement of disease remission and reduction of corticosteroid dose.The mean age ± standard deviation of patients was 69 ± 8 years. The main...